VRDN Q4 2017 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+57.7% YoY

Gross Profit

-$4M-319.3% margin

Operating Income

-$6M-533.1% margin

Net Income

-$6M-535.7% margin

EPS (Diluted)

$-4.30

QoQ Revenue Growth

-26.9%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$716,000

Balance Sheet

Total Assets

$52M

Total Liabilities

$14M

Stockholders' Equity

$39M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$756,000	+57.7%
Gross Profit	-$4M	$64,000	-6046.9%
Operating Income	-$6M	-$5M	-16.1%
Net Income	-$6M	-$6M	-14.6%